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Methadone is highly effective as a maintenance pharmacotherapy for opioid dependence but
also exhibits several shortcomings. Of particular concern is the frequency with which patients
report inadequate suppression of withdrawal symptoms or adverse effects despite seemingly
adequate doses and the application of an individualised approach to dosing. The principal
aim of this thesis was to evaluate slow-release oral morphine (SROM) as an alternative
maintenance pharmacotherapy to methadone for the treatment of opioid dependence. Eighteen
methadone maintenance patients reporting adequate (holders) or inadequate (non-holders)
withdrawal suppression between doses were recruited to participate in an open-label,
randomly-ordered crossover clinical trial of methadone and SROM. The study featured the
concurrent measurement of plasma drug concentrations and both subjective and physiological
indices of opioid effect throughout a 24-hour inter-dosing interval on one occasion for
methadone and SROM after at least 4 weeks on a stable dose of each drug. Other foci
included comparisons of clinical efficacy and acceptability and assessments of opioid
withdrawal during the transition between medications. Compared to methadone, SROM was
at least as effective overall in suppressing opioid withdrawal between doses and was
associated with improved social functioning, fewer and less severe side effects, greater drug
liking, reduced heroin cravings, and an enhanced sense of feeling 'normal', and yielded
similar outcomes for measures of drug use, depression and health. The majority of patients
stated a preference for SROM (78%) over methadone (22%), including 89o/o of the non-
holders and 690/o of the holders. The most frequently cited reasons for preferring SROM
included fewer side effects, better withdrawal suppression, improved sleep, feeling more
normal, improved health, and improved energy. Transfer from methadone to SROM was not
associated with a prohibitive degree of opioid withdrawal, providing that an appropriate dose
conversion ratio was applied. These findings suggest that SROM is a safe and efficacious
maintenance pharmacotherapy for opioid dependence that may be particularly advantageous
as an alternative for patients responding poorly to methadone. Further large-scale clinical
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